VYNE Therapeutics, Inc. (NASDAQ: VYNE) is engaged as a clinical-stage biopharma company, which is focused on the research and development of proprietary and innovative therapeutics to treat immune-inflammatory conditions. Shares of the biopharmaceutical company are rallying 31% through afternoon trading on Wednesday, April 19, 2023. Over the past three months, VYNE Therapeutics has seen average daily volume of 20,620 shares. However, volume of 33.52 million shares or dollar volume of around $137.1 million, has already exchanged hands through afternoon trading.

Shares of VYNE Therapeutics are climbing after the company disclosed promising preclinical results demonstrating the potential of its pan-BET inhibitor, VYN201, in treating idiopathic pulmonary fibrosis (IPF). In a widely recognized preclinical IPF model, VYN201 exhibited substantial anti-inflammatory and anti-fibrotic effects at 0.5 mg/ml and 1 mg/ml doses. VYN201 treatment significantly reduced lung fibrosis and hydroxyproline levels, while improving blood oxygen saturation and functional lung volume. These findings support the potential of VYN201 as a powerful, locally-administered therapy for various immuno-inflammatory conditions, validating the InhiBET™ BET inhibitor platform.

As a locally-administered “soft” drug, VYN201 targets multiple inflammatory cell signaling pathways with minimal systemic exposure. The encouraging data reveals its potential as a potent anti-inflammatory and anti-fibrotic agent, with applications across various immuno-inflammatory conditions. VYN201’s effectiveness in reducing lung fibrosis, hydroxyproline levels, and improving blood oxygen saturation and functional lung volume highlights its potential to transform the treatment landscape for IPF and related diseases.

“The data from this well-validated preclinical model of IPF clearly demonstrates VYN201’s potential to deliver a potent anti-inflammatory and anti-fibrotic response,” said David Domzalski, President and Chief Executive Officer of VYNE. “These data in IPF support our thesis that VYN201 has potential utility as a locally-administered therapy across a variety of immuno-inflammatory indications and further underscores the potential value of our InhiBET^TM BET inhibitor platform.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post VYNE Therapeutics (NASDAQ: VYNE) Shares Positive Preclinical Data for VYN201 as a Potential Treatment for Idiopathic Pulmonary Fibrosis appeared first on Spotlight Growth.